Conflict of interest: none.
Original Clinical Article
Article first published online: 27 JUL 2012
Copyright © 2012 Wiley Periodicals, Inc.
Neurourology and Urodynamics
Volume 32, Issue 3, pages 238–241, March 2013
How to Cite
Cameron, A. P., Anger, J. T., Madison, R., Saigal, C. S., Clemens, J. Q. and the Urologic Diseases in America Project (2013), Battery explantation after sacral neuromodulation in the medicare population. Neurourol. Urodyn., 32: 238–241. doi: 10.1002/nau.22294
Dirk De Ridder led the peer-review process as the Associate Editor responsible for the paper.
- Issue published online: 18 MAR 2013
- Article first published online: 27 JUL 2012
- Manuscript Accepted: 2 JUL 2012
- Manuscript Received: 8 MAY 2012
- NIDDK (Urologic Diseases in America Project). Grant Number: N01 DK012460
- interstitial cystitis;
- outcome assessment;
- overactive urinary bladder;
- sacral neuromodulation
To determine sacral neuromodulation battery life and the patient and provider risk factors for early explantation in a population-based sample.
A 5% sample of Medicare beneficiaries from 1997 to 2007 served as the data source. All patients who had a sacral neuromodulation device implanted in that time period were included. Variables included in a multivariate analysis of risk factors for removal included gender, age, race, diagnosis, type of test phase, provider specialty, and volume. The number of device reprogramming events was also recorded in this time period.
Mean follow-up was 60.5 months. Patients on average had 2.15 reprogramming episodes in their first year, with that number decreasing over subsequent years. Out of the 558 batteries implanted 63 (11.3%) were explanted. Of the 19 implanted individuals who carried the diagnosis of interstitial cystitis (IC), 11 (57.9%) had the battery removed. This was the only variable that predicted early removal, with an odds ratio of explantation of 10.5 (95% CI: 3.9–28.4).
Very few sacral neuromodulation batteries, once implanted, are removed prematurely. Patients with IC, however, are at very high risk of requiring premature battery removal. Neurourol. Urodynam. 32: 238–241, 2013. © 2012 Wiley Periodicals, Inc.